teicoplanin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
glycopeptide antibacterials (Actinoplanes strains) 2998 61036-62-2

Description:

MoleculeDescription

Synonyms:

  • teicoplanin
  • Antibiotic 8327A
  • Antibiotic MDL 507
  • targocid
  • targosid
  • teichomycin
Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 210.83 26.36 92 5572 29456 46650942
Multiple organ dysfunction syndrome 95.91 26.36 66 5598 51644 46628754
Septic shock 93.73 26.36 68 5596 57825 46622573
Thrombocytopenia 92.21 26.36 94 5570 126487 46553911
Rash maculo-papular 82.89 26.36 48 5616 27826 46652572
Pyrexia 81.89 26.36 149 5515 348653 46331745
Toxic epidermal necrolysis 78.82 26.36 43 5621 22235 46658163
Acinetobacter infection 70.54 26.36 19 5645 1403 46678995
Bronchopulmonary aspergillosis 68.94 26.36 28 5636 7468 46672930
Pancytopenia 56.16 26.36 60 5604 84998 46595400
Stenotrophomonas infection 54.61 26.36 16 5648 1604 46678794
Neutropenia 52.36 26.36 75 5589 143129 46537269
Enterococcal infection 50.53 26.36 22 5642 6965 46673433
Sepsis 49.37 26.36 71 5593 135943 46544455
Febrile neutropenia 49.26 26.36 59 5605 94568 46585830
Drug resistance 49.21 26.36 29 5635 17339 46663059
Stevens-Johnson syndrome 48.56 26.36 32 5632 23265 46657133
Acute generalised exanthematous pustulosis 47.27 26.36 23 5641 9382 46671016
Eosinophilia 46.50 26.36 29 5635 19188 46661210
Fatigue 46.28 26.36 9 5655 608688 46071710
Mental status changes postoperative 43.63 26.36 9 5655 206 46680192
Confusion postoperative 42.98 26.36 9 5655 222 46680176
Pathogen resistance 40.33 26.36 18 5646 6042 46674356
Fungaemia 39.07 26.36 13 5651 1978 46678420
Rash erythematous 37.47 26.36 32 5632 34318 46646080
Disseminated intravascular coagulation 36.94 26.36 25 5639 18980 46661418
Haemostasis 36.77 26.36 8 5656 238 46680160
Morganella infection 36.62 26.36 9 5655 461 46679937
Haemodynamic instability 36.16 26.36 18 5646 7707 46672691
Acute kidney injury 35.35 26.36 84 5580 235771 46444627
Thrombotic microangiopathy 34.92 26.36 18 5646 8288 46672110
Rash macular 34.28 26.36 24 5640 19236 46661162
Hepatic function abnormal 33.39 26.36 30 5634 34391 46646007
Toxic skin eruption 33.30 26.36 20 5644 12367 46668031
Headache 32.47 26.36 9 5655 478343 46202055
Renal impairment 31.71 26.36 42 5622 74330 46606068
Periventricular leukomalacia 31.48 26.36 6 5658 90 46680308
Anaphylactic reaction 30.75 26.36 35 5629 53077 46627321
Posterior reversible encephalopathy syndrome 29.62 26.36 20 5644 15121 46665277
Folate deficiency 28.92 26.36 10 5654 1708 46678690
Red man syndrome 28.62 26.36 9 5655 1144 46679254
Graft versus host disease in gastrointestinal tract 28.60 26.36 11 5653 2539 46677859
Neutropenic sepsis 28.31 26.36 18 5646 12306 46668092
Dermatitis bullous 27.70 26.36 15 5649 7628 46672770
Cholestasis 27.19 26.36 24 5640 26869 46653529
Agranulocytosis 26.95 26.36 22 5642 22163 46658235
Graft versus host disease in liver 26.91 26.36 7 5657 451 46679947
Fall 26.84 26.36 4 5660 329093 46351305

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 117.57 20.79 77 7017 28411 29916973
Pyrexia 87.08 20.79 205 6889 294284 29651100
Septic shock 72.32 20.79 82 7012 63525 29881859
Disseminated intravascular coagulation 68.07 20.79 50 7044 22121 29923263
Systemic candida 63.14 20.79 24 7070 2740 29942644
Venoocclusive disease 61.01 20.79 23 7071 2567 29942817
Multiple organ dysfunction syndrome 59.21 20.79 74 7020 63413 29881971
Fatigue 57.70 20.79 5 7089 320668 29624716
Eosinophilia 52.79 20.79 43 7051 22117 29923267
Rash maculo-papular 51.65 20.79 45 7049 25373 29920011
Sepsis 50.91 20.79 109 6985 146286 29799098
Thrombocytopenia 47.60 20.79 102 6992 136942 29808442
Renal impairment 44.52 20.79 75 7019 84109 29861275
Neutropenia 41.58 20.79 93 7001 128447 29816937
Staphylococcal infection 37.80 20.79 41 7053 30183 29915201
Systemic mycosis 36.83 20.79 13 7081 1203 29944181
Dizziness 35.09 20.79 3 7091 194906 29750478
Norovirus test positive 34.15 20.79 7 7087 76 29945308
Stevens-Johnson syndrome 33.49 20.79 30 7064 17526 29927858
Hyphaema 31.91 20.79 9 7085 399 29944985
Acute kidney injury 31.44 20.79 138 6956 273704 29671680
Graft versus host disease 31.38 20.79 23 7071 10127 29935257
Febrile neutropenia 30.95 20.79 74 7020 106619 29838765
Dermatitis exfoliative 30.33 20.79 20 7074 7436 29937948
Hepatic function abnormal 30.02 20.79 43 7051 41902 29903482
Fungal infection 29.48 20.79 25 7069 13575 29931809
Cytomegalovirus infection 29.39 20.79 32 7062 23642 29921742
Death 29.39 20.79 25 7069 357258 29588126
Cytomegalovirus test positive 28.70 20.79 15 7079 3630 29941754
Staphylococcal sepsis 28.20 20.79 21 7073 9470 29935914
Respiratory gas exchange disorder 27.17 20.79 8 7086 414 29944970
Platelet count decreased 26.97 20.79 70 7024 106059 29839325
Enterococcal infection 26.25 20.79 19 7075 8205 29937179
Geotrichum infection 26.15 20.79 8 7086 472 29944912
C-reactive protein increased 26.02 20.79 41 7053 43432 29901952
Anaphylactic reaction 25.06 20.79 32 7062 27950 29917434
Drug resistance 24.62 20.79 27 7067 20106 29925278
Mast cell degranulation present 23.02 20.79 5 7089 73 29945311
Asthenia 22.84 20.79 12 7082 221278 29724106
Condition aggravated 22.72 20.79 78 7016 137788 29807596
Necrotising ulcerative gingivostomatitis 22.10 20.79 5 7089 89 29945295
Flavobacterium infection 21.84 20.79 5 7089 94 29945290
Cholestasis 21.50 20.79 28 7066 24922 29920462
Pancytopenia 21.49 20.79 56 7038 84996 29860388
Toxic skin eruption 21.35 20.79 19 7075 10996 29934388
Haemophagocytic lymphohistiocytosis 21.22 20.79 18 7076 9773 29935611

Pharmacologic Action:

SourceCodeDescription
ATC J01XA02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Staphylococcal infectious disease indication 56038003

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4025272 VUID
N0000171799 NUI
D02142 KEGG_DRUG
4025272 VANDF
C0678137 UMLSCUI
CHEBI:29687 CHEBI
CHEMBL4297166 ChEMBL_ID
CHEMBL2367892 ChEMBL_ID
133065662 PUBCHEM_CID
D017334 MESH_DESCRIPTOR_UI
5155 INN_ID
DB06149 DRUGBANK_ID
4U3D3YY81M UNII
10924 IUPHAR_LIGAND_ID
196469 RXNORM
003765 NDDF
387529008 SNOMEDCT_US
96014005 SNOMEDCT_US

Pharmaceutical products:

None